Featured Article: Serum [Met 5]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone

Exp Biol Med (Maywood)
September 2017
https://pubmed.ncbi.nlm.nih.gov/28766982/

Emerging Unconventional Therapies for Alopecia Areata

J Investig Dermatol Symp Proc
January 2018
https://pubmed.ncbi.nlm.nih.gov/29273103/

Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis

Exp Biol Med (Maywood)
February 2018
https://pubmed.ncbi.nlm.nih.gov/29307283/

The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia

Int J Pharm Compd
June 2018
https://pubmed.ncbi.nlm.nih.gov/29878893/

Compounded Low-dose Naltrexone for the Treatment of Guttate Psoriasis: A Case Report

Int J Pharm Compd
August 2018
https://pubmed.ncbi.nlm.nih.gov/30021181/

Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy

Int Immunopharmacol
August 2018
https://pubmed.ncbi.nlm.nih.gov/29885638/

Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion

Cureus
10 July 2018
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126779/

Low-dose naltrexone: A possible safe effective treatment for autoimmune disease and cancer

Anti-Aging Therapeutics, Volume 12, Chapter 3
January 2009
https://books.google.co.il/books?id=BSfzEE0tT9cC&lpg=PR7&dq=low%20dose%20naltrexone&pg=PR7#v=onepage&q=low%20dose%20naltrexone&f=false

The Long Term Suppression of Experimental Autoimmune Encephalomyelitis by the Opioid Growth Factor and Low Dose Naltrexone

The FASEB Journal
01 April 2011
https://doi.org/10.1096/fasebj.25.1_supplement.677.6 

Intermittent blockade of OGFr and treatment of autoimmune disorders

Exp Biol Med (Maywood)
December 2018
https://pubmed.ncbi.nlm.nih.gov/30541348/